CureVac inks lung cancer vaccine deal with Boehringer for up to $600M

CureVac has made its second notable deal with Big Pharma this year, this time partnering with Boehringer Ingelheim to offer its investigational lung cancer vaccine in a $45 million deal with potential milestone payments of up to $556 million.

Under the deal, Boehringer Ingelheim will gain global commercial rights to CureVac's CV9202, an experimental therapeutic mRNA vaccine in early clinical development for the treatment of non-small cell lung cancer (NSCLC).

The German pharma giant plans to pair it with Gilotrif (afatinib) for advanced or metastatic epidermal growth factor receptor-mutated NSCLC as well as in combination with chemo-radiation therapy in patients with unresectable--or inoperable--stage III NSCLC.

Designed to mobilize a patient's own immune system into action against a tumor, CV9202 is a combination of mRNA molecules coding for 6 antigens overexpressed in lung cancer.

CV9202 and its predecessor, CV9201, also from the RNActive series, were tested in initial clinical trials by CureVac and showed promising activity in generating immune responses against all antitumor antigens. One of the biggest draws of CureVac's RNActive vaccines lies in their ability to withstand high temps and unintentional freezing.

In July, Sanofi's ($SNY) vaccine unit tapped CureVac in a $205 million-plus deal for an mRNA-based vaccine intended for an undisclosed pathogen.

- read the release
- get FierceBiotech's take

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.